- Home
- GH
as 05-09-2025 4:00pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 5.5B | IPO Year: | 2018 |
| Target Price: | $52.81 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.01 - $52.92 | Next Earning Date: | 04-30-2025 |
| Revenue: | $773,996,000 | Revenue Growth: | 28.20% |
| Revenue Growth (this year): | 19.53% | Revenue Growth (next year): | 21.92% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tariq Musa | GH | Director | Apr 17 '25 | Sell | $44.79 | 116 | $5,195.64 | 3,345 | |
| Tariq Musa | GH | Director | Mar 19 '25 | Sell | $43.70 | 116 | $5,069.20 | 3,345 | |
| Kalia Kumud | GH | Chief Information Officer | Mar 15 '25 | Sell | $43.16 | 3,500 | $151,060.35 | 19,720 | |
| Joyce Meghan V. | GH | Director | Mar 3 '25 | Sell | $42.71 | 100 | $4,271.00 | 7,647 | |
| Tariq Musa | GH | Director | Feb 20 '25 | Sell | $48.33 | 116 | $5,606.28 | 3,345 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Guardant Health to Participate in Upcoming Investor Conferences
Business Wire
a day ago
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
Business Wire
2 days ago
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 days ago
Guardant Health Insider Sold Shares Worth $5,936,572, According to a Recent SEC Filing
Simply Wall St.
6 days ago
Guardant Health, Inc. (NASDAQ:GH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$59.17
MT Newswires
7 days ago
Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating
Simply Wall St.
7 days ago
Guardant Health First Quarter 2025 Earnings: Beats Expectations
Morningstar Research
8 days ago
Analyst Report: Guardant Health, Inc.
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.